Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer - Orionis Biosciences Orionis Biosciences has announced a second collaboration with Genentech, worth $105 million upfront and up to $2 billion in potential milestone payments, to develop small-molecule glue medicines for o...

Sharing news today of another #Genentech collaboration! Very proud and excited to be shaping the future of medicine with the #Orionisbio Team 💪orionisbio.com/2025/05/genentech-collab...